GetTopicDetailResponse(id=80d2108841bf, topicName=復發(fā)難治性大B細胞淋巴瘤, introduction=復發(fā)難治性大B細胞淋巴瘤, content=axi-cel 復發(fā)難治性大B細胞淋巴瘤, image=null, comments=0, allHits=763, url=null, type=1, isShow=1, status=1, isAdmin=null, adminId=5395722, adminEncryptionId=cade5395722, adminName=梅斯管理員, createdBy=cade5395722, createdName=梅斯管理員, createdAvatar=, createdTime=Tue Dec 19 15:31:01 CST 2023, time=2023-12-19, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=484686, tagList=[TagDto(tagId=484686, tagName=復發(fā)難治性大B細胞淋巴瘤)], ipAttribution=上海, topicAdmin=0, lengthMark=0)
[GetTopicListResponse(id=2265702, encodeId=f48c2265e02bb, content=<a href='/topic/show?id=2fbd12485119' target=_blank style='color:#2F92EE;'>#CAR-NK細胞療法#</a> <a href='/topic/show?id=80d2108841bf' target=_blank style='color:#2F92EE;'>#復發(fā)難治性大B細胞淋巴瘤#</a>, objectTitle=【Nat Cancer】4-1BB共刺激的CD19 CAR-NK治療R/R LBCL的中國多中心I期研究, objectType=article, longId=878025, objectId=50f28e802526, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20220804/1659603269411_8252897.webp, objectUrl=/article/show_article.do?id=50f28e802526, replyNumber=0, likeNumber=24, createdTime=2025-05-19, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=50f28e802526, moduleTitle=【Nat Cancer】4-1BB共刺激的CD19 CAR-NK治療R/R LBCL的中國多中心I期研究, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=50f28e802526)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2175883, encodeId=ab5921e5883c3, content=<a href='/topic/show?id=b633108840b8' target=_blank style='color:#2F92EE;'>#axi-cel#</a> <a href='/topic/show?id=80d2108841bf' target=_blank style='color:#2F92EE;'>#復發(fā)難治性大B細胞淋巴瘤#</a>, objectTitle=【Blood Adv】axi-cel治療LBCL的橋接治療不影響生存：美國淋巴瘤CART聯(lián)盟研究, objectType=article, longId=805533, objectId=0948805533c7, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/medical-staff-meeting-GXNVP9J.jpg, objectUrl=/article/show_article.do?id=0948805533c7, replyNumber=0, likeNumber=106, createdTime=2023-12-19, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=0948805533c7, moduleTitle=【Blood Adv】axi-cel治療LBCL的橋接治療不影響生存：美國淋巴瘤CART聯(lián)盟研究, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=0948805533c7)], followStatus=false, userIsMember=false, type=null, lengthMark=0)]
梅斯管理員
2023-12-19發(fā)表于上海
